Teradyne Flips the Script: Test Equipment Now Outruns Wafer Fab Spending

The Long-Awaited Reversal

Teradyne's second-quarter 2026 results were a loud declaration that the semiconductor test industry has shed its laggard status. Total revenue topped $1.3 billion, up over 100% year-over-year, with non-GAAP EPS of $2.47, up over 300%. But the real story wasn't just the beat — it was the structural narrative shift. CEO Gregory Smith articulated a clear thesis: “the trend reversed in 2024 and test is now outpacing fab equipment” — Gregory S. Smith, Chief Executive Officer · 2026-07-29. For over a decade, test grew slower than wafer fab equipment (WFE); now, with WFE CapEx forecast to approach $250 billion this year and $200 billion by the end of the decade, Smith sees a path for the overall ATE TAM to reach or exceed $20 billion.

This is far from idle chatter. The company is explicitly tying its growth to transistor and bit production—the fundamental drivers of test demand. Share gain, bit growth, and value chain are now the top keywords in its trajectory, reflecting a pivot from test as a cyclical afterthought to a structural growth engine. The total revenue in Q1 2026 already hit $1.28B, up 87% YoY, and Q2 surpassed it, confirming the acceleration.

AI Is Everywhere

AI-driven revenue now accounts for over 60% of Teradyne's total. The company's data center strategy spans from wafer to rack: compute, memory, HBM, NAND, board test, optical interconnect, and even robotics. The merchant GPU breakthrough—first order delivered in Q2 and a second hyperscaler correlation completed—signals real share gains in a market Teradyne has been largely shut out of for two decades. Smith noted the dual-vendor qualification process takes nine to twelve months, and “you will start to see some of the effect of share change in 2027,” but it will be gradual.

Memory is another bright spot. Revenue hit a record $212M, driven by HBM and DRAM strength, and the company highlighted a “resurgence in NAND.” The test insertion complexity in HBM and the increasing test intensity of AI accelerators are expanding the TAM in ways that benefit Teradyne directly.

Riding the Wave, but with Risk

While the outlook is bullish, the market is not complacent. The stock closed 22% below its June 30 peak, and the 90-day price trend is flat. The company guided to a first-half weighting of 50-52% of annual revenue, implying strength in the back half, but also acknowledged “softness in mobile and order timing in compute.” Gross margins are expected to dip to 58-59% in Q3 due to product mix and new product launches, a reminder that the accelerated growth comes with volatility.

Still, the management team's confidence is backed by investments: R&D, go-to-market, and capital expenditures are rising to capture the opportunity. They plan to update their target earnings model in Q4, which should provide a more concrete path to sustained growth.

The Verdict

Teradyne has become a pivotal enabler of the AI build-out, and its new narrative—test as a leading indicator of semiconductor capex, not a lagging one—is compelling. The company is no longer just riding the AI wave; it's helping shape it. With the ATE TAM expected to double by 2030 and Teradyne positioned to gain share through dual sourcing and advanced packaging, the next few quarters will be critical. If the momentum holds, the stock's drawdown will look like a distant memory.

We see a path for overall ATE TAM to reach or exceed $20 billion by the end of the decade.